Cellenkos, Inc., a clinical-stage biotechnology company developing allogeneic regulatory T cell (Treg) therapies, has unveiled new data from its investigational product CK0804, presented at the 67th American Society of Hematology (ASH) Annual Meeting. The findings highlight the potential of a dose-intensive regimen of CK0804 to reduce spleen volume, improve symptoms, and lower transfusion dependence in patients with myelofibrosis who had an inadequate response to JAK inhibitor therapy. Notably, the study included patients with thrombocytopenia, a subgroup often excluded from advanced trials due to high treatment-related risks. Based on these data, the company plans to initiate a Phase 2 study in this resistant patient population.

Why a Treg cell therapy targeting inflammation matters in JAK inhibitor-resistant myelofibrosis

JAK inhibitors such as ruxolitinib and fedratinib remain foundational therapies in myelofibrosis, yet they provide limited durability and face dose constraints in patients with cytopenias. Up to 50 percent of patients become refractory or intolerant to JAK inhibitors over time, and those with baseline thrombocytopenia are particularly underserved due to treatment-limiting myelosuppression. Cellenkos is aiming to fill this void by addressing a different pathophysiological axis. Rather than modulating JAK-STAT signaling, CK0804 works through the immunoregulatory function of allogeneic Tregs, which are designed to suppress the chronic inflammatory milieu that drives disease progression in advanced myelofibrosis.

In the presented study, 13 patients received CK0804, with 11 deemed evaluable. A subset received a dose-intensive schedule involving weekly infusions for four weeks followed by monthly administration. The company reported spleen volume reduction of at least 10 percent in 45 percent of patients, and symptom burden dropped by more than 50 percent in 78 percent of participants. All three transfusion-dependent patients showed decreased blood product requirements. In thrombocytopenic individuals, the tolerability and efficacy were especially noteworthy. Two of three thrombocytopenic patients experienced measurable spleen volume reduction, and all reported complete symptom resolution.

Industry analysts see this as an important data point for a population that has historically lacked options. If future trials replicate these outcomes, CK0804 could emerge as a front-runner in the post-JAK space, especially for patients ineligible for dose-intensified chemotherapy or stem cell transplant.

What dose intensification reveals about early response kinetics and inflammation control

One of the more striking aspects of the CK0804 data was the apparent advantage of dose intensification in generating clinical response. Four patients received an intensified regimen of weekly infusions, which correlated with more rapid symptom control and reductions in inflammatory cytokine biomarkers, including fibroblast growth factor (FGF), soluble CD40 ligand, and platelet-derived growth factor AA and BB isoforms. These cytokines are implicated in both bone marrow fibrosis and splenic extramedullary hematopoiesis.

The implication is that aggressive early Treg delivery may be necessary to recalibrate immune homeostasis in patients with high inflammatory burden. Researchers familiar with the field have noted that these reductions in biomarkers were consistent with spleen volume changes, reinforcing the mechanistic link. While biomarker correlation does not imply causality, the coherence between clinical and molecular endpoints strengthens the case for pursuing this therapeutic model.

Further investigation will be required to determine whether dose intensity translates to long-term benefit or simply shortens time to response. Still, in a disease where rapid symptomatic relief is often a clinical priority, the potential for accelerated impact cannot be overlooked.

Why Cellenkos’ dose-intensive Treg therapy could disrupt treatment for cytopenic myelofibrosis

CK0804 is derived from umbilical cord blood and processed using Cellenkos’ proprietary CRANE platform. It is designed to be an off-the-shelf, allogeneic Treg product that does not require HLA matching or any patient-specific conditioning regimen. The company emphasized that the therapy is administered via intravenous infusion in an outpatient setting and has a shelf life exceeding two years in cryopreserved form.

This model addresses two of the central barriers in cell therapy: production scalability and clinical logistics. By enabling same-day outpatient dosing, the company is aiming to circumvent the delays and costs associated with autologous manufacturing. A single cord blood unit can reportedly yield multiple therapeutic doses, supporting batch-scale manufacturing economics. However, industry observers caution that consistency of potency and phenotype across scaled batches remains a key challenge in cell-based therapeutics. While Cellenkos operates an in-house cGMP facility in Houston, Texas, larger commercial deployment will require validation of lot-to-lot reproducibility under regulatory scrutiny.

Should the upcoming Phase 2 trial deliver sustained clinical benefit with minimal toxicities, Cellenkos’ model could serve as a scalable precedent for Treg therapy in other immune-driven conditions.

Regulatory watchers see opportunity for biomarker-guided development, but warn of gaps

Given the relatively small size of the Phase 1 cohort, the roadmap to regulatory acceleration will likely depend on the design and outcomes of the planned Phase 2 trial. The incorporation of validated biomarkers and well-defined clinical endpoints will be critical. The absence of a comparator arm in early-stage studies may limit the interpretability of efficacy claims. Nonetheless, regulators have shown increased openness to inflammation-targeted cell therapies, especially in rare hematologic indications with high unmet need.

Clinical development teams will need to demonstrate not only durability of spleen and symptom control, but also the ability to define responder subsets. The thrombocytopenic cohort may serve as a particularly important segment, given the lack of safe treatment alternatives. If CK0804 maintains efficacy in this group, the trial could set the stage for breakthrough designation, provided the biomarker story continues to strengthen.

One area of uncertainty is the long-term persistence of Treg activity post-infusion. While patients in the ASH presentation tolerated multiple infusions without evidence of significant immunogenicity, data on in vivo persistence, trafficking, and re-dosing requirements remain sparse. These will need to be addressed through peripheral blood and marrow immunophenotyping in subsequent trial phases.

ALS program signals broader ambitions with CNS-targeted Treg platform

Beyond myelofibrosis, Cellenkos is also advancing CK0803, a CNS-homing Treg product designed for neuroinflammatory conditions. In October 2025, the U.S. Food and Drug Administration granted Orphan Drug Designation to CK0803 for the treatment of amyotrophic lateral sclerosis (ALS), based on encouraging data from a small proof-of-concept study and preliminary Phase 1 results.

CK0803 is engineered to express a distinct chemokine receptor profile, including high levels of CXCR3 and CXCR7, allowing for preferential migration across the blood-brain barrier. Patients in early trials, particularly those with spinal-onset ALS, showed a slowdown in disease progression based on ALS Functional Rating Scale-Revised (ALSFRS-R) scores and a consistent reduction in plasma neurofilament levels, a recognized biomarker of neurodegeneration. The product has been well tolerated, with no dose-limiting toxicities observed, and is administered without the need for IL-2 supplementation or conditioning.

Clinicians tracking the ALS field are cautiously optimistic but note that small cohorts and absence of control arms make interpretation difficult. The durability of motor function preservation, rather than biomarker changes alone, will be essential to move this program toward registrational potential.

Dual-track strategy positions Cellenkos as a Treg platform contender in rare disease

With CK0804 in hematologic inflammation and CK0803 in neurodegeneration, Cellenkos is pursuing a dual-track strategy targeting diseases where pathologic inflammation is central to progression and current therapies fall short. The use of cryopreserved, outpatient-compatible allogeneic products provides a potentially scalable model, though success will depend heavily on near-term clinical readouts.

The upcoming Phase 2 study for CK0804 will be pivotal in determining whether the early signal in JAK-resistant myelofibrosis can translate into regulatory momentum and commercial viability. Similarly, continued progress in ALS with CK0803 could open the door to broader neuroinflammatory applications, from frontotemporal dementia to multiple sclerosis.

Ultimately, the company’s ability to execute on manufacturing, patient selection, and regulatory strategy across two complex therapeutic areas will define its trajectory over the next 24 months.

  ALS, Cellenkos Inc., CK0803, CK0804, CRANE platform, JAK inhibitor resistance, myelofibrosis, neuroinflammation, regulatory T cells